MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis

About this update from Moonlake Immunotherapeutics

MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody ® sonelokimab in active psoriatic arthritis First placebo-controlled randomized trial in active psoriatic arthritis (PsA) using a Nanobody® to report positive topline results in support of potential best-in-class profile Primary endpoint ACR50 met with up to 47% (p

View stock analysis, news, and events for Moonlake Immunotherapeutics